Abstract

The dual face of NAMPT: Intracellular/extracellular protein and diagnostic/therapeutic target in cancer.

Highlights

  • Since the discovery of nicotinamide phosphoribosyltransferase (NAMPT) as a pre-B cell-enhancing factor in 1994 by Samal et al [1], many papers have described the pleiotropic function of this enzyme

  • A vital role of NAMPT in mammalian cells was attributed to its activity as a rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide (NAD) from nicotinamide, and was supported by its widespread tissue distribution and by the embryonic lethality of total NAMPT knock-out mice [2]

  • It is clear in the field that it is necessary to select tumours uniquely addicted to NAMPT activity in the generation of NAD

Read more

Summary

Introduction

Since the discovery of nicotinamide phosphoribosyltransferase (NAMPT) as a pre-B cell-enhancing factor in 1994 by Samal et al [1], many papers have described the pleiotropic function of this enzyme. A common strategy that several tumour types adopt to sustain NAD production is to overexpress NAMPT, regulated at the transcriptional level [5].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call